In March 2025, two new versions of the Nomenclature of Medical Biology Procedures (NABM 95 and 96) were released. No new tests were added. The reimbursement tariffs for several existing tests were adjusted, and one test was removed.

MTRC is pleased to announce the release of its latest White Paper: "Innovative Payment Schemes for Medical Devices". White Paper offers a summary of innovative payment schemes for medical devices that permit direct applications by the Med Tech industry, including the Innovative Devices Access Pathway (IDAP) in the UK, Forfait Innovation and Article 51 in France, and co-funded clinical studies under §137e in Germany.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Sustainability Publications Digest. In a recent publication, Vanderwee et al. introduced a pragmatic decision-making approach for healthcare facilities with tools to select environmentally sustainable alternatives to replace single-use options. A cross-sectional multi-center survey in Belgian hospitals was performed, followed by an exploratory analysis of the sustainability of commonly used healthcare materials. The authors developed a structured assessment method, combining real-world procurement data and literature-based evaluations to inform sustainable, safe, and cost-effective material choices.

On March 4, 2025, the Member State Coordination Group on Health Technology Assessment (HTACG) published submission (‘briefing’) templates for Joint Scientific Consultations (JSC) of medical devices and in-vitro diagnostics under the EU HTAR framework. Health Technology Developers submit completed briefing templates as part of the briefing package to be considered for JSC. The JSC Outcome Document template was published as well.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Health Economic Publications Digest. In a recent publication, Elsner et al. conducted a literature review to evaluate the economic value of cardiovascular implantable electronic devices for heart failure treatment, with a focus on the European context over the past 10 years. The review assessed the economic implications of various device therapies, including cardiac resynchronization therapy with a pacemaker (CRT-P), CRT with a defibrillator (CRT-D), implantable cardioverter-defibrillators (ICDs), pacemakers, and (semi)automated telemonitoring, using QALYs and ICERs as standardized measures of cost-effectiveness. All cardiovascular implantable electronic devices were found to fall within commonly accepted cost-effectiveness thresholds.

In February 2025, the Ministry of Health and Care Services published a National Cancer Strategy for 2025-2030. The strategy outlines five key target areas with corresponding goals and actions. The target areas comprise pioneering cancer prevention and early detection, improving patient outcomes, enhancing user-oriented cancer care, increasing survival rates and longevity, and ensuring the best possible quality of life. The actions include the expansion of national screening initiatives, the accreditation of Comprehensive Cancer Centers, digital home monitoring, precision diagnostics, and the establishment of a national healthcare innovation hub.

MTRC is pleased to announce the release of its latest White Paper: "Challenges and Proposed Solutions in Systematic Literature Reviews for Medical Devices." This White Paper addresses challenges such as limited high-quality studies, variability in clinical outcomes due to operator experience, and evolving device generations. By addressing these critical challenges, MTRC empowers stakeholders in the medical technology sector to navigate the complexities of evidence assessment confidently.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. In a recent publication, Arcà et al. conducted a comparative analysis of national HTA frameworks for digital therapeutics (DTx) assessed in Germany, the UK, and France. By analyzing cross-country HTAs for two digital therapeutic products, the study revealed substantial differences in assessment criteria and evidence requirements. Despite the divergence, there was a shared emphasis on product positioning within the clinical pathway, the appropriateness of chosen comparators, and considerations of usability. Safety received limited attention, but a request is often made for the addition and evaluation of risk-flagging systems.

In March 2025, the Health Sciences Institute in Aragon released a document that provides guidance on incorporating real-world data into health technology assessment, focusing on the preadoption phase for evaluating new technologies in the Spanish Network of HTA Agencies (RedETS) framework. It outlines a workflow aligning with RedETS practices, identifying key milestones where RWD adds value and offering methods and tools to integrate RWD into decision models.

MTRC, a leading boutique Med Tech market access consultancy in Europe, is looking for a Director of Health Economics and Outcomes Research.

MTRC, a leading boutique Med Tech market access consultancy in Europe, is looking for a Director of Market Access.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its EU HTA Publications Digest. In a recent publication, Gsteiger et al. explored the conceptual divergence between “technology assessment” and “technology appraisal” in the context of the new EU HTA Regulation. The authors advocated for a clearer distinction between scientific evaluation and value judgments to ensure effective implementation and avoid ambiguity. The study emphasized the importance of transitioning from centralized assessments to national-level appraisal processes that reflect local value judgments and uncertainties.